Site last updated:
February 2010
Cancer Services Forum currently has 552 registered members
Articles
The Editorial Advisory Board invites the submission of articles and opinion pieces on any topic regarding the commissioning and provision of cancer services in the UK.
Recent articles include
BOPA & UKONS Conference 2009
0 comment on this article -
Be the first to comment
The first ever joint BOPA (British Oncology Pharmacy Association) annual symposium and UKONS (UK Oncology Nursing Society) annual conference took place this month in Brighton.
A total of 675 delegates attended over the 4 days, and the busy exhibition hall, which held 53 stands, contributed a vibrant feel to proceedings. But with more than 50 talks, meetings and workshops, not to mention numerous posters, the emphasis was firmly on work. Read on for a comprehensive report.
The Kennedy report: Appraising the value of innovation and other benefits
0 comment on this article -
Be the first to comment
This summer has seen the publication of the Kennedy report, which includes 25 recommendations aimed at improving relations between the National Institute for Health and Clinical Excellence (NICE), the pharmaceutical industry and the general public.
Cancer Services Forum hears from Alison Clough, ABPI and Christopher McCabe, Leeds Institute of Health Economics and colleagues. Please feel free to enter the discussion and post your own views in the box provided.
The New NICE Guidelines for Management of Breast Cancer—A Personal Commentary
0 comment on this article -
Be the first to comment
Earlier this month, the nation was shocked to hear that the NHS was set to go bust in 2011 unless it prepared to make some serious cuts in spending.
In this edition of Cancer Services Forum, Professor Chris Poole’s personal commentary on the new NICE guidelines for breast cancer provides a colourful account of what he describes as NICE rationing. He discusses some controversial issues around continuing inequalities, a perceived non-transparency of data analysis and the problems with clinical trial crossover when looking for meaningful endpoints on which to base funding decisions.
Chemotherapy: Putting Patient Safety First
0 comment on this article -
Be the first to comment
In the past 2 months we have seen the publication of three major reports that will have an impact on the way chemotherapy is delivered in future years.
The report on chemotherapy from NCEPOD (National Confidential Enquiry into Patient Outcome and Death), For better, for worse?, makes disturbing reading. Although we are using increasing amounts of cancer chemotherapy, there are many aspects of governance and collaborative working across organisational boundaries that need to be improved to make sure patients have access to safe services. Please read on for analysis of these reports and a comment from Alison Jones, Chair of the Association of Cancer Physicians.
Chemotherapy delivery: challenges for the future
0 comment on this article -
Be the first to comment
As a result of the rising incidence of cancer and the expanding range of treatments available, UK cancer services are working under growing pressure.
In this article Gill Donovan discusses national and local strategies for coping with the demand for cancer care, looking specifically at the issues of patient capacity and the drive to deliver cancer treatments nearer to patients’ homes.
Time To Stop Hiding Behind The Skirts of NICE—The UK Renal Cell Carcinoma Expert
0 comment on this article -
Be the first to comment
The recently produced Cancer Commissioning Toolkit will aid commissioners in making informed decisions about the services that they commission. Darzi points us to ensuring that services are high quality and as local as possible, whilst World Class Commissioning ensures that this approach is safe and leads to a reduction in health inequalities.
The UK Renal Cell Carcinoma Expert Group highlights a key issue that commissioning will have to tackle—the availability of drugs. The group looks at the example of the renal cell carcinoma drugs, sunitinib and sorafenib and equality of care within the constraints of available funding.
